Although there is no cure for narcolepsy, medication and lifestyle changes can help manage the symptoms. Medicines that ...

People who live with narcolepsy — about one out of every 2,000 Americans — don’t have many options when it comes to treatment. The milder form of narcolepsy includes symptoms of excessive ...

We report a case of narcolepsy in a four-year-old girl to provide insights into the early diagnosis and treatment of narcolepsy in children. As a chronic condition, narcolepsy can lead to decreased ...

Though narcolepsy is a rare condition, it occurs commonly enough, with type 1 affecting about one in 5,000 people. The diagnosis should be made by a sleep specialist who is able to apply the proper ...

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

Axsome Therapeutics, Inc. AXSM announced that the FDA has approved Symbravo (meloxicam and rizatriptan) for the acute ...

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

Cataplexy is the least common symptom of these, and many people with narcolepsy never experience it. Narcolepsy with cataplexy is called narcolepsy type 1, while narcolepsy without cataplexy is ...

and Nuvigil® (armodafinil), both of which are indicated for the treatment of Excessive Daytime Sleepiness (EDS) in adults with narcolepsy. Neuraxpharm has acquired these products in most markets ...

Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda said it's laser-focused on six pipeline assets that could each reel in ...

AXSM stock is riding on upbeat preliminary 2024 results. The company's depression drug, Auvelity, drives its top line while ...

E-2086 is under clinical development by Eisai and currently in Phase I for Narcolepsy. According to GlobalData, Phase I drugs for Narcolepsy have an 80% phase transition success rate (PTSR) indication ...